Recently,
Moderna (MRNA) has seen a surge in its stock price following a year-to-date rally, leading investors to question whether it is priced too high. The company has faced its share of challenges, including struggles with its flu vaccine and a potential $2.25 billion settlement. However, the news that the
FDA's controversial vaccine lead plans to exit led to a significant popularity spike. In legal news, Moderna agreed to a $950 million settlement to bring an end to a long-running patent litigation with
Genevant and Arbutus, a move that has also boosted its stock value. The company hopes to further its progress with the pending approval of a
combined mRNA vaccine for flu and COVID. The FDA reversed its decision and agreed to review Moderna's flu vaccine, demonstrating progression in its vaccine trial efforts. However, continuation in vaccine trials is reportedly being slowed due to US backlash. Nevertheless, Moderna's skin cancer vaccine, developed in partnership with
Merck, has shown sustained benefits in a five-year follow-up. Moderna is also paying Roivant up to $2.25 billion to settle a patent lawsuit behind mRNA vaccines.
Moderna MRNA News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sun, 08 Mar 2026 00:17:00 GMT -
Rating 7
- Innovation 8
- Information 5
- Rumor 4
